Source: iQoncept / Shutterstock
Cartesian Therapeutics (NASDAQ:RNAC) just reported results for the first quarter of 2024.
- Cartesian Therapeutics reported earnings per share of -$10.50. This was below the analyst estimate for EPS of -88 cents.
- The company reported revenue of $5.84 million.
- This was 367.20% better than the analyst estimate for revenue of $1.25 million.
Article printed from InvestorPlace Media, https://investorplace.com/earning-results/2024/05/rnac-stock-earnings-cartesian-therapeutics-for-q1-of-2024/.
©2024 InvestorPlace Media, LLC